PMC4090435_01
PMC4090435_02
Major treatments, events, and laboratory results in the clinical course. Panel shows a timeline of the recipient's clinical course until discharge, with arrows indicating points of administration of rituximab and HBIG. Periods of steroids, MMF, PVIT, tacrolimus, and entecavir are indicated by the gray bars. Results of CD19- and CD20-positive B cell count, isoagglutinin titers of anti-A and anti-B, and HBs-Ab are shown below the graph.
CRIT2014-507621.001.jpg
PMC4090435_02_CRIT2014-507621.001.jpg
fig1
Figure 1. Following LDLT, an additional 375 mg/m2 of rituximab was administered to the recipient, and steroids, MMF, and tacrolimus were administered.